Core Viewpoint - NovaBridge Biosciences has received FDA alignment on givastomig's potential eligibility for an accelerated approval pathway in specific gastric cancer patients, paving the way for a Phase 3 trial to begin in Q4 2026 [1][7]. Company Overview - NovaBridge is a global biotechnology platform focused on accelerating access to innovative medicines, combining business development expertise with clinical development to advance breakthrough assets [6]. Givastomig Development - Givastomig is a bispecific antibody targeting Claudin 18.2-positive tumor cells, designed to activate T cells in the tumor microenvironment, and is being developed for gastric cancer and other gastrointestinal malignancies [4][10]. - The Phase 1b trial showed a 75% objective response rate (ORR), with 77% ORR at 8 mg/kg and 73% at 12 mg/kg, alongside a median progression-free survival (mPFS) of 16.9 months and an 82% six-month landmark PFS rate [8]. Regulatory Milestones - The FDA confirmed givastomig's eligibility for an accelerated approval pathway, with the primary endpoint for the upcoming Phase 3 trial being the objective response rate [7]. - The company plans to present detailed Phase 1b expansion data at a major medical conference in the second half of 2026 [3]. Collaborative Development - Givastomig is being developed in partnership with ABL Bio, with NovaBridge as the lead party sharing worldwide rights, excluding Greater China and South Korea [5].

Core Insights - NovaBridge Biosciences (NASDAQ:NBP) shares increased following positive Phase 2a study results for VIS-101, a treatment for retinal vascular diseases [1] Trial Data - The Phase 2a study showed that VIS-101 led to rapid and durable treatment responses in patients with wet age-related macular degeneration (wet AMD), which affects over 20 million people globally [2] - VIS-101 demonstrated mean Best Corrected Visual Acuity (BVCA) improvements of over 10 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters and median central subfield thickness (CST) reductions of 100-150 mm [2][3] - The study enrolled 38 patients in China and showed a favorable safety profile with no dose-limiting toxicity, positioning VIS-101 as a potential best-in-class treatment option [3] Future Plans - The company plans to initiate a dose-determining Phase 2b study in the second half of 2026, followed by a global Phase 3 program in 2027 [3] Technical Analysis - NovaBridge shares have decreased by 23.08% over the past 12 months, indicating a challenging year for the stock [5] - Currently, the stock is trading 14.2% above its 20-day simple moving average (SMA) and 4.4% above its 50-day SMA, suggesting short-term strength despite a longer-term downtrend [5] - The RSI is at 51.92, indicating neutral territory, while the MACD is at -0.0639, suggesting a bullish signal as it is above the signal line [6] Price Action - NovaBridge Biosciences shares were up 8.86% at $3.81 at the last check, with key resistance at $4.50 and key support at $3.50 [7]

NovaBridge Biosciences Update Summary Company Overview - **Company**: NovaBridge Biosciences (NasdaqGM:IMAB) - **Focus**: Global biotech platform with a hub-and-spoke business model, primarily in ophthalmology and oncology sectors - **Lead Assets**: - **VIS-101**: A molecule targeting VEGF-A and ANG-2, designed for retinal vascular diseases - **Givastomig**: A bispecific antibody for gastric cancer, targeting Claudin 18.2 and 4-1BB - **Financial Position**: As of the last SEC filing, the company has $228 million in cash, providing operational runway through 2028 [5][6] Industry Context - **Market Need**: Over 57 million people globally are affected by retinal vascular diseases, including wet AMD, diabetic macular edema, and retinal vein occlusion, indicating a significant unmet need for effective therapies [16][17] - **Competitive Landscape**: Current treatments like Lucentis and Eylea have shorter treatment intervals, while VIS-101 aims for longer intervals (Q8 to Q24 weeks) [18][19] Clinical Development - **VIS-101 Phase IIa Trial**: - **Design**: Multicenter, open-label, randomized study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with neovascular AMD [25][26] - **Patient Population**: 38 patients randomized in a 2-to-1 ratio to receive either 6 mg or 3 mg of VIS-101 [26] - **Results**: - Rapid and robust BCVA gain observed, with approximately 70% of treatment-naive patients being treatment-free at 4 months and about 40% at 6 months [31][32] - Central subfield thickness (CST) decreased by over 100 microns after the first injection [31] - Safety profile: Well-tolerated with no dose-limiting toxicities reported [34] Key Findings - **Durability**: VIS-101 demonstrated a potential best-in-class durability with treatment-free intervals extending up to 24 weeks [40] - **Comparison with Competitors**: VIS-101 shows double the anti-VEGF inhibition and 17 times the anti-ANG-2 inhibition compared to faricimab [35] - **Management Team**: Led by experienced professionals, including Dr. Emmett Cunningham, who has a strong background in ophthalmology and drug development [11][12] Future Plans - **Next Steps**: - Initiation of Phase IIb study in China in the second half of 2026 - Global Phase III program expected to begin in 2027 [40][41] - **Partnership Strategy**: Open to discussions for partnerships but currently does not require one for global development [70] Additional Insights - **Clinical Trial Design**: The trial's retreatment criteria were designed to prioritize patient safety, requiring either a decrease in vision or an increase in anatomical parameters for retreatment [53] - **Regulatory Considerations**: Future trials will likely focus on treatment-naive patients, as regulatory agencies prefer this population for clearer efficacy assessments [79] This summary encapsulates the key points from the NovaBridge Biosciences update, highlighting the company's strategic focus, clinical advancements, and future directions in the biotech landscape.

Core Insights - NovaBridge Biosciences and its subsidiary Visara, Inc. announced positive topline results from the Phase 2a study of VIS-101, a dual VEGF-A X ANG-2 inhibitor for retinal vascular diseases, showing rapid and durable treatment responses in wet AMD [1][2][4] Group 1: Study Results - VIS-101 demonstrated rapid and robust efficacy with mean improvements in Best Corrected Visual Acuity (BCVA) of over 10 ETDRS letters and median central subfield thickness (CST) reductions of 100-150 mm [4][5] - Nearly half of treatment-naïve patients remained retreatment-free for more than six months after three loading doses, indicating potentially best-in-class durability [2][3][5] - The study enrolled 38 patients aged 50-80 years with wet AMD, randomized into 6 mg (n=25) and 3 mg (n=13) dosing groups, with baseline characteristics being similar [7][11] Group 2: Safety Profile - VIS-101 exhibited a favorable safety profile with no dose-limiting toxicity; treatment-related adverse events were 0% in the 3 mg group and 8% in the 6 mg group [9][4] - The data supports the potential of VIS-101 to provide significant benefits to patients with wet AMD and other retinal vascular diseases [3][6] Group 3: Future Development Plans - A Phase 2b dose-determining study is expected to begin in the second half of 2026, followed by a global Phase 3 program anticipated to start in 2027 [4][20] - The positive data from the Phase 2a study is seen as an important milestone for Visara and NovaBridge, enhancing the visibility of their value-creation potential [6][20]

Core Viewpoint - VIS-101 is a dual VEGF-A/ANG-2 inhibitor designed to offer more effective and durable treatment for patients with wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) [1][2][11] Company Overview - NovaBridge Biosciences is a global biotechnology platform company focused on accelerating access to innovative medicines [7] - The company combines business development expertise with clinical development to advance breakthrough assets [7] - NovaBridge is the majority shareholder of Visara, which holds global rights to VIS-101 outside of Greater China and certain Asian territories [3][6] Product Development - VIS-101 is currently undergoing a randomized, dose-ranging Phase 2a study for wet AMD [2][11] - The product is designed to provide potent and durable treatment benefits for wet AMD, DME, and RVO [2][11] - The company will host a virtual business update call to review Phase 2a clinical data for VIS-101 on March 9, 2026 [1] Pipeline and Collaborations - NovaBridge's pipeline includes givastomig, a bispecific antibody targeting Claudin 18.2 for gastric cancer, and ragistomig, a bispecific antibody for solid tumors [8][10] - The company also owns worldwide rights to uliledlimab, an anti-CD73 antibody targeting immunosuppression in cancer [10]

Core Insights - NovaBridge Biosciences is a global biotechnology platform company focused on accelerating access to innovative medicines [2] - The company will participate in the Leerink Partners 2026 Global Healthcare Conference from March 8-11, 2026, with a presentation scheduled for March 11 at 8:00 AM ET [1] Company Overview - NovaBridge combines business development expertise with agile translational clinical development to advance breakthrough assets [2] - The company aims to bridge science, strategy, and execution to facilitate the rapid progression of transformative therapies from discovery to patients [2] Product Pipeline - The leading product in NovaBridge's pipeline is givastomig, a bispecific antibody targeting Claudin 18.2, currently in a global Phase 2 study for gastric cancer [3][4] - VIS-101, another key product, targets VEGF-A and ANG-2 for treating wet age-related macular degeneration and diabetic macular edema, and is completing a Phase 2a study [5] Collaborations and Rights - NovaBridge collaborates with ABL Bio for the development of ragistomig, a bispecific antibody for solid tumors [4] - The company holds worldwide rights outside of China for uliledlimab, an anti-CD73 antibody targeting immunosuppression in cancer [4]

Core Viewpoint - NovaBridge Biosciences has appointed Dr. Emmett T. Cunningham, Jr. as Vice Chairman of the Board, which is expected to enhance the company's strategic direction and shareholder value through his extensive biopharma experience [1][3][7]. Company Overview - NovaBridge is a global biotechnology platform focused on accelerating access to innovative medicines, combining business development expertise with agile clinical development to advance breakthrough assets [9]. - The company operates a unique hub-and-spoke business model aimed at bridging the gap between unmet patient needs and transformative care [3][7]. Leadership Appointment - Dr. Cunningham brings over 25 years of experience in biopharma, having held leadership roles in venture capital and major pharmaceutical companies, including Blackstone Group and Pfizer [2][5][6]. - His appointment is seen as a positive endorsement of NovaBridge's mission to create shareholder value by expediting the development of transformative medicines [7]. Research and Development Focus - Dr. Cunningham will also join the Research and Development Committee of the Board, which is established to expedite innovation and long-term growth [7]. - The company is currently developing several drug candidates, including givastomig and VIS-101, targeting various cancers and eye diseases [10][12]. Pipeline Highlights - Givastomig is a bispecific antibody being evaluated in a Phase 2 study for Claudin 18.2-positive gastric cancer, following positive results from a Phase 1b study [11]. - VIS-101 is in a Phase 2a study for wet age-related macular degeneration and diabetic macular edema, aiming to provide more durable treatment benefits [12].

Core Insights - NovaBridge Biosciences has initiated a global Phase 2 randomized study for givastomig, a bispecific antibody targeting Claudin 18.2, in combination with nivolumab and chemotherapy for HER2-negative metastatic gastric cancer [1][2][3] - The Phase 1b results demonstrated a 75% objective response rate (ORR) and a median progression-free survival (mPFS) of 16.9 months, indicating strong efficacy and potential for givastomig to become a best-in-class therapy [3][4][5] - The gastric cancer market is projected to reach $12 billion by 2030, highlighting significant commercial potential for givastomig [1][3] Study Details - The Phase 2 study will enroll approximately 180 patients and aims to confirm the efficacy and safety of givastomig in a broader patient population [5] - Primary endpoint is progression-free survival (PFS), with secondary endpoints including ORR, overall survival (OS), duration of response (DoR), and disease control rate (DCR) [5] Clinical Data - Phase 1b data showed that patients treated with givastomig at 8 mg/kg and 12 mg/kg had an ORR of 77% and 73% respectively, with durable responses and good tolerability [4][3] - The study's results are expected to be presented in 2027, with updated Phase 1b results anticipated in the second half of 2026 [2][3] Product Overview - Givastomig is designed to activate T cells in the tumor microenvironment, targeting Claudin 18.2-positive tumor cells, and is being developed for gastric and other gastrointestinal cancers [7][11] - The product is being developed in partnership with ABL Bio, with NovaBridge holding worldwide rights outside of Greater China and South Korea [8]

Core Insights - Fu Wei, Executive Chairman of NovaBridge Biosciences, intends to purchase up to $5,000,000 of the Company's American Depository Shares (ADSs) in open market transactions, starting from January 15, 2026 [1] - The Company has executed a new business strategy in 2025, which has positioned it for growth, supported by positive Phase 1b dose expansion data for its drug candidate, givastomig [2][3] Company Overview - NovaBridge is a global biotechnology platform focused on accelerating access to innovative medicines, combining business development expertise with clinical development to advance breakthrough assets [4] - The Company’s pipeline includes givastomig, a bispecific antibody targeting Claudin 18.2, and VIS-101, a bifunctional biologic targeting VEGF-A and ANG2 [5] Drug Development - Givastomig is designed to treat Claudin 18.2-positive gastric cancer and is currently in clinical development [6] - VIS-101 is completing a Phase 2 study for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) [7]

Core Viewpoint - NovaBridge Biosciences has been included in the Nasdaq Biotech Index, highlighting its status as an industry leader and enhancing its visibility in the biotechnology sector [3][8]. Company Overview - NovaBridge is a global biotechnology platform focused on accelerating access to innovative medicines by combining business development expertise with agile clinical development [3]. - The company aims to bridge science, strategy, and execution to advance transformative therapies from discovery to patients [3]. Key Developments - Fu Wei, Executive Chairman, and Sean Fu, CEO, will ring the Nasdaq Opening Bell on January 2, 2026, marking a significant milestone for the company [2][9]. - The inclusion in the Nasdaq Biotech Index became effective on December 19, 2025, which is seen as a validation of NovaBridge's strategic vision and pipeline [3][8]. Product Pipeline - The leading product in NovaBridge's pipeline is givastomig, a bispecific antibody targeting Claudin 18.2, aimed at treating gastric cancer and other gastrointestinal malignancies [4][5]. - VIS-101, another key product, targets VEGF-A and ANG-2 for treating wet age-related macular degeneration and diabetic macular edema, currently in a Phase 2 study [6]. Strategic Collaborations - NovaBridge is collaborating with ABL Bio on ragistomig, a bispecific antibody designed for solid tumors, and holds worldwide rights outside of China for uliledlimab, an anti-CD73 antibody [5].